In additional embodiments, the number of T cells is expanded at least 500 fold during the culture of step d).

In further embodiments, the number of T cells is expanded at least 600 fold during the culture of step d).

In certain embodiments, the method further comprises recovering the manufactured T cell therapeutic.

In certain embodiments, recovering the T cell therapeutic comprises concentrating and washing the cells expanded in step d).

In particular embodiments, the T cell therapeutic is concentrated and washed using a semiautomated flowthrough centrifuge.

In further embodiments, the semiautomated flowthrough centrifuge is a Cell Saver 5+ or LOVO.

In particular embodiments, the method further comprises cryopreserving the T cell therapeutic.

In additional embodiments, the cryopreserved T cells are thawed for use in a method of adoptive cell therapy.

Disclosed is a composition comprising the manufactured T cells of any one of the preceding embodiments described *supra* and elsewhere herein and a physiologically acceptable excipient is provided.

In various other embodiments, a method of treating a malignancy in a subject in need thereof, comprising administering to the subject the T cell therapeutic of any one of the preceding embodiments described *supra* and elsewhere herein is provided.

Disclosed is use of the composition as described herein in the manufacture of a medicament for treating a malignancy in a subject in need thereof is provided.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Figure 1 shows transduction efficiency and VCN of transduced cells transduced at different times during the T cell manufacturing process. Cells were transduced with a GFP expressing lentivirus at 1-2 x 108 TU/106 PBMCs at D0, D1, and D2. FACS analysis of GFP expressing cells expressing CD3, CD8, or CD4 determined that transduction efficiency and VCN were highest in cells transduced 20 to 24 hours (D1) after activation.

Figure 2 shows the transduction efficiency of cells activated using different methods. PBMCs were activated using (i) plate bound anti-CD3 and anti-CD28 antibodies; (ii) soluble anti-CD3 and anti-CD28 antibodies; and (iii) bead bound anti-CD3 and anti-

49. The method of Claim 48, wherein the T cell therapeutic is concentrated and washed using a semiautomated flowthrough centrifuge.

50. The method of Claim 49, wherein the semiautomated flowthrough centrifuge is a Cell Saver 5^+ or LOVO.

51. The method of any one of Claims 47 to 50, wherein the method further comprises cryopreserving the T cell therapeutic.